By Philip Astley-Sparke, CEO of Replimune, as part of the From The Trenches feature of LifeSciVC. I recently stepped down after a six-year stint as Chairman of uniQure (NASDAQ: QURE). In the process of interviewing potential successors, one candidate observed

By Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC It’s tempting to think that the first skill you need to learn in business development is negotiating. That’s important, of course, but it should

By Ankit Mahadevia, CEO and Founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. The opportunity for each member of a NewCo to take on multiple responsibilities selects early for people ready to help a

By Tim Reilly & Jonathan Montagu, CDO and CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4)

By Sam Truex, Venture Partner at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. Holy cow, have we seen the rain lately – both downpours outside and a downpour of SPAC activity. In October 2020, Bruce

By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC When I play board games, I play to win. That requires thinking several moves ahead. In the game Risk, for instance, it’s not

By Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera Therapeutics, as part of the From The Trenches feature of LifeSciVC. The inherent ability to combine the power of genetic-like knockdown with the flexibility of small molecules; the power to

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC I was in the passenger seat, trying desperately not to reach for the grab handle, saying reassuring things but thinking ‘those mailboxes are really

By Andrea DiMella, VP and Head of Talent at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Spring in New England is in full bloom. All around birds are chirping, flowers are blooming, and there is

The universe of public biotech companies has been growing for a decade, and increasingly so in the past few years as the IPO market has flourished. Hundreds of young aspiring biotechs have tapped into the public equity markets, swelling the

The biotech job market is a bit like the suburban housing market—red hot. It’s a buyer’s market, don’t waive your inspection rights! By Pamela L. Esposito, CBO of Replimune as part of the From The Trenches feature of LifeSciVC. It

Co-authored by Jodie Morrison and René Russo, former CEO of Cadent Therapeutics and CEO of Xilio Therapeutics, respectively.   Over the last 5 years, biotech executives have been increasingly focused on the importance of greater diversity in our companies. As two